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Abstract
This is a follow up study of a multicenter randomised placebo-controlled trial in seven cen-
tres in five West European countries. The RCT assessed the effect of infant formula supple-
mented with a mixture of prebiotics (with neutral short-chain and long-chain
oligosaccharides and pectin-derived acidic oligosaccharides) during infancy in term-born
children (n=1130). In the follow-up study 672 children (60% of the study population) partici-
pated: 232 (56%) from the prebiotics group (PG), 243 (58%) from the control group (CG),
and 197 (66%) from the non-randomised breast-fed group (BG). The primary outcome was
the occurrence of febrile episodes at three to five years of age prospectively documented by
the parents: in the PG 1.17 (interquartile range 0.50-2.08) episodes per year versus 1.20
(0.52-2.57) in the CG; and 1.48 (0.65-2.60) in the BG. This specific prebiotics mixture given
during infancy in healthy non-atopic subjects does not decrease febrile episodes and there-
fore seems not to prevent infection between their third and fifth birthday.
Introduction
Reduction of infections is one of the major health advantages of breastfeeding compared to for-
mula feeding. [1] Human milk oligosaccharides may contribute to this effect substantially as
they have been implicated in the development of the gut flora of breastfed infants. [2–4]
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Supplementation of infant milk formula with oligosaccharides might represent an option to
modulate the intestinal microbiota of formula fed infants as well as acting as immunomodula-
tory substances and supporting systemic processes contributing to innate defence. In vitro
studies show an immunomodulatory effect of human milk oligosaccharides as demonstrated
by maturation and cytokine production of cord blood T-cells and by influencing various devel-
opmental stages in intestinal cells. [5–6] Mouse model studies show an effect on the vaccina-
tion response and on the number of lactobacilli in the coecum of oligosaccharide-induced
immune modulation, suggesting a role for microbiota. [7] Another study in mice showed a re-
duction of pulmonary infections in mice fed oligosaccharides. [8] Several clinical studies in
human infants have shown a lower incidence of infections when fed with formula to which a
combination of probiotics and prebiotics was added. [9–11] The effect of supplementation of
prebiotics alone was studied by Arslanoglu et al, who found a lower incidence of respiratory in-
fections and diarrhea in children up to two years of age after receiving prebiotics during the
first 6 months of life. [12] In contrast with these findings,our randomised controlled trial com-
paring the number of fever episodes in healthy term born infants who received either a prebiot-
ic mixture or placebo did not find a decrease in febrile episodes during the first year of life after
receiving prebiotics. Instead we found a small decrease in such episodes during the first six
months, during which the exposure to prebiotics was highest. [13] Stool consistency was softer
in the prebiotics group and closer to that of the breastfeeding group and no difference in ad-
verse events in the two formula groups was found. [14]
Although we found limited results of efficacy in the first year of life, we hypothesized that a
long term beneficial effect might exist. An effect after two years was found by Arslanoglu et al.
[12] A large population-based infant feeding study showed a reduced number of infections in
children at 7 years of age associated with the use of breastfeeding. [1] To date, no study has as-
sessed the effect of supplementation with prebiotics given during the first month of life on in-
fections in children older than two years, i.e. more than a year after the exposure to prebiotics
has stopped. We assessed the long term effect of dietary supplementation with prebiotics (6.8
g/L neutral and 1.2 g/L acidic oligosaccharides) to infants in the first year of life on the occur-
rence of infections in these children at three to five years of age.
Patients and Methods
We followed healthy full term born infants, who participated in a randomised, double-blind,
placebo controlled, multicentre trial (MIPS1), from infancy to five years of age. This study was
registered with the German Clinical Trials Register DRKS00000201. Infants randomised to the
PG received a standard non-hydrolysed cow’s milk-based formula to which a mixture of neu-
tral short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (6.8g/l, ratio
9:1, Immunofortis; Nutricia Cuijk BV, Cuijk, The Netherlands) and pectin-derived acidic oli-
gosaccharides (1.2 g/l) had been added. Details of the RCT (n = 1130) have been published else-
where. [13] All together 1001 children completed the RCT (MIPS1).
Procedures in the RCT (MIPS1)
We included healthy full term infants (37 to 42 weeks of gestational age) with a birth weight
above the 10th percentile for gestational age according to locally applicable growth charts.
Infants at risk for atopic diseases, i.e. those with a first degree relative with a history of asth-
ma, allergic rhinitis, or atopic dermatitis, were excluded. Infants with neonatal diseases requir-
ing antibiotic treatment, and infants who had previously received formulae containing
prebiotics or probiotics were also excluded.
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Mothers who could not or did not fully breast-feed their infants were asked to participate in
the study and to be randomised to one of the two formula groups before the child reached
eight weeks of age. If the parents gave their consent, randomisation occurred the same day.
Thus, randomisation and start of the study formula was done at any time before eight weeks
after birth.
Parents were invited to participate with their child in the follow-up study if their child had
completed the RCT (MIPS1), and if they had not moved to another area. We did not exclude
those children who had received treatment with antibiotics, or those who had received supple-
mentation with prebiotics or probiotics. The follow up study took place from November 2008
to February 2011. The study was approved by all local ethical review boards of the participating
hospitals: Ethikkommission, Ethikausschuß 2 am Campus Virchow Klinikum, Berlin, Ger-
many; Medisch Ethische Toetsingcommissie, Universitair Medisch Centrum Groningen, The
Netherlands; Comitato Etico, Ospedale Maggiore Policlinico,Mangiagalli E Regina Elena; Mi-
lano, Italy; Ethikkommission für das Bundesland Salzburg, Austria; Ethikkommission am Kin-
derspital/Kantonale Ethikkommission Zürich, Switzerland; Comitato Etico Indipendente
Ospedale Fatebenefratelli e Oftalmico, Azienda Ospedaliera di rilievo nazionale, Milano, Italy;
and Comitato Etico, Spedali Civili, Brescia, Italy. Written informed consent was obtained from
each parent. The parents and children were unaware of the group allocation, as were the study
physicians and study nurses. The latter only evaluated the infants and were not involved in the
statistical analysis and interpretation of the data. None of the researchers who were previously
involved in the statistical analysis and interpretation of the data for the MIPS1 study report
were involved in the evaluation of any follow-up study participant. An episode of fever was the
primary outcome. Follow-up was from the children’s third to fifth birthday. The parents were
contacted every three months. At the time of inclusion they were given a diary and were asked
to indicate on a form in the diary every day whether their child had fever, and to also report
coughing, wheezing, runny or blocked nose, vomiting, diarrhoea, and other symptoms. Fever
was defined as a peak rectal temperature of 38.5°C. We also asked the parents to indicate
whether the child had received vaccinations, and whether they had been given antibiotic and
antipyretic treatment.
A sample size was not calculated; we included as many children as possible from amongst
those who completed the MIPS1 study.
The statistical analyses were performed with SAS, Version 9 (SAS Institute, Cary, NC). All
analyses were performed using two-sided testing. Significance level for all testing was 0.05. Per
centre the analyses were performed with stratification. The primary analyses were performed
using the full analysis set consisting of all children who had been randomised in the PG or the
CG, or who had been included in the BG (non-randomised) in MIPS1 according to the inten-
tion to treat principle. The PG group and the CG group consisted of children who had received
the randomised study formula exclusively up to the age of 20 weeks as well as those who had re-
ceived the study formula plus breastfeeding. The BG group consisted of children who had re-
ceived breastfeeding exclusively up to the age of 20 weeks as well as children who had received
breastfeeding plus supplemental formula feeding according to the local standards, according to
the parents’ preference. Table 1 shows the number of patients included in the MIPS follow up
study and attrition during the study period (the first 16 weeks of life) of the groups receiving
exclusive study formula and exclusive breastfeeding. At eight weeks of age, 70.7% of all rando-
mised infants in PG and 67.1% in CG received exclusive study formula. These percentages in-
creased up to 84.9% and 84.8%, respectively. At eight weeks 92.9% of all children in BG
received exclusive breastfeeding, decreasing to 83.8% at 16 weeks.
The primary outcome variable was defined as: (frequency of fever episodes + 0.05) divided
by (duration of observational period in days + 0.1). This ‘adjustment’ was done in order to
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avoid ‘zero’ for those cases with no episode of fever. Furthermore, by this ‘adjustment’ the du-
ration of the observational period, including the observational period of those cases with zero
fever episodes could be taken into account. [15] The observational period (which is the time at
risk in which the number of fever episodes was counted) started at inclusion in the MIPS follow
up study which was the third birthday. To present the frequency of fever episodes per year, fre-
quency was multiplied by 365.1 days. By using this technique the frequency of fever episodes
per child could be calculated. Similar calculations were done for the frequency of episodes with
coughing, wheezing, runny or blocked nose, vomiting, diarrhoea, and other symptoms. We
also calculated the duration of these symptoms. Differences in the frequency of symptoms per
year and in the duration of symptoms in the PG versus the CG group; and the CG versus the
BG group, were analysed for all centres using the non-parametric Van Elteren test. This is a
stratified Wilcoxon rank sum test. Results are presented in median values with their 25 and 75
percentiles. Differences between groups with respect to baseline characteristics, vaccinations,
and the use of antibiotics and antipyretics were analysed using a non-parametric test (two-
sided, Mann Whitney).
Results
We included 672 (60% of the 1130 participants in MIPS1) in the MIPS follow up study. Of the
original study population (n = 1130), 458 children were not included in the follow-up study:
129 children did not complete the RCT (MIPS1), and another 329 children could no longer be
contacted because they had moved to another area or had changed their contact information.
We included 232 (56% of the 414 participants in this group in MIPS1) from the PG, 243 (58%)
from the CG, and 197 (66%) from the BG (Fig 1).
Differences in baseline characteristics, including those which may be associated with the
outcome, were compared within the treatment groups (PG and CG) between the original
MIPS1 study population versus the MIPS follow up study population. The only statistically sig-
nificant difference we found was in the number of rooms in the house in the PG (MIPS1
(n = 414) 3 (3–4) rooms versus in MIPS follow-up (n = 232) 4(3–5) rooms), and in the CG
(MIPS1 (n = 416) 3 (3–4) rooms versus in MIPS follow-up (n = 243) 4 (3–4) rooms). This was
similar in the Prebiotics Group and the Control Group.
The baseline characteristics at the beginning of the MIPS follow-up study are presented in
Table 2. We found no statistically significant differences between the PG and the CG. Median
age of inclusion in the RCT was 30 days of life for the prebiotics group (PG), 32 days for the
control group (CG), and 50 days for the breast fed group (BG). Table 3 shows the data about
the vaccination pattern in the PG, CG, and BG. There were no statistical differences between
the PG and CG.
Table 1. Exclusive study formula and exclusive breastfeeding per 2 week time point in the first 16
weeks of life.
Week PG (n = 232) CG (n = 243) BG (n = 197)
8 164 (70.7%) 163 (67.1) 183 (92.9)
10 187 (80.6%) 198 (81.5) 171 (86.8)
12 189 (81.5%) 206 (84.8) 178 (90.4)
14 196 (84.5%) 201 (82.7) 174 (88.3)
16 197 (84.9%) 206 (84.8) 165 (83.8)
PG—Prebiotics Group; CG—Control Group; BG—Breast-fed Group
doi:10.1371/journal.pone.0129927.t001
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Table 4 shows the adjusted frequency of fever episodes and other illness symptoms during
follow-up. We found no statistically significant differences between the PG and the CG in the
occurrence of fever and other illnesses: in the PG 1.17 (median value, interquartile range 0.50–
2.08) febrile episodes per year were reported versus 1.20 (0.52–2.57) in the CG (p = 0.22); and
1.48 (0.65–2.60) in the BG. We found a higher frequency of ‘other symptoms’ runny or blocked
nose in the BG versus the CG.
In Table 5 we present the duration of illness episodes in days. There was a shorter duration
of ‘diarrhoea’ in the PG versus the CG (P = .01).
In Table 6 the use of antibiotics is shown, with no statistical significant differences between
the two study formula groups. Table 7 shows the use of antipyretics. We found no statistical
significant differences between the two study formula groups.
Discussion
In this study we show that it is unlikely that dietary prebiotic supplementation in the first year
of life has an effect on the frequency of febrile episodes in otherwise healthy non-atopic chil-
dren during their third to their fifth year. We found a reduction of one day of the duration of
episodes of diarrhoea (Table 5). The clinical significance of this finding may be limited, al-
though shortening the duration of illness by a day is certainly relevant for parents.
Fig 1. Flow diagram.
doi:10.1371/journal.pone.0129927.g001
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In the MIPS1 study we failed to find an effect of prebiotic supplementation in reducing the
frequency of febrile episodes in the first year of life while previously we found a small difference
in the frequency of febrile episodes in the first six months in the PG versus the CG (both medi-
an values 0.13, P<0.05) in favour of the PG. [13] In an additional post hoc ‘per protocol’ analy-
sis, we used the data of the participants who had either received prebiotic formula or the
Table 2. Baseline characteristics.
Prebiotics Group (PG)
(n = 232)2
Control Group (CG)
(n = 243)2
Breast-fed Group (BG)
(n = 197)2
PG vs CG1 P
value
Children
Age at inclusion (days) 30 (19–43) 32 (21–46) 50 (38–54) 0.25
Age at inclusion in MIPS FU (months) 36 (35–36) 36 (35–36) 36 (35–36) 0.42
Birth weight (grams) 3263 (2960–3600) 3290 (2910–3630) 3480 (3160–3700) 0.96
Weight at inclusion (kilograms) 15.0 (13.9–16.1) 14.8 (13.8–16.0) 14.7 (13.8–15.8) 0.35
Boys 113 (48.7) 114 (46.9) 91 (46.2) 0.70
Vaginal delivery 147 (63.3) 154 (63.4) 167 (84.8) 0.99
Number of children in household 2 (1–2) 2 (1–2) 2 (2–2) 0.72
Parents
Smoking mother
-Before pregnancy 80 (34.6) 80 (33.1) 57 (28.9) 0.72
-During pregnancy 32 (13.9) 26 (10.7) 14 (7.1) 0.30
-Since child’s 1st birthday 58 (25.1) 56 (23.1) 31 (15.7) 0.62
Smoking father
-Since child’s 1st birthday 72 (31.4) 84 (35.4) 48 (24.5) 0.36
Preschool admission
-At 3 years of age 121 (52.2) 127 (52.3) 101 (51.3) 0.98
-At 5 years of age 126 (54.3) 131 (53.9) 119 (60.4) 0.24
Education level of the mother 0.47
-Primary and secondary school 74 (31.9) 82 (33.8) 56 (28.4)
-Some university education/post-secondary education/
technical or trade qualiﬁcation
114 (49.1) 106 (43.8) 92 (46.7)
-Completed university degree 44 (19.0) 54 (22.3) 49 (24.9)
Mother occupational status 0.07
-Employed 157 (67.7) 166 (68.9) 134 (68.7)
-Self-employed 16 (6.9) 26 (10.8) 13 (6.7)
-Seeking work/Student/Unemployed 11 (4.7) 3 (1.2) 5 (2.6)
-Not working 48 (20.7) 46 (19.1) 43 (22.0)
Education level of the father 0.21
-Primary and secondary school 78 (34.4) 71 (29.7) 41 (21.0)
-Some university education/post-secondary education/
technical or trade qualiﬁcation
106 (46.7) 107 (44.8) 100 (51.0)
-Completed university degree 43 (18.9) 61 (25.5) 55 (28.0)
Father occupational status >0.99
-Employed 176 (77.5) 184 (77.3) 138 (70.8)
-Self-employed 43 (19.0) 45 (18.9) 47 (24.1)
-Seeking work/Student/Unemployed 7 (3.1) 8 (3.4) 8 (4.1)
-Not working/Disabled 1 (0.4) 1 (0.4) 2 (1.0)
1 Non-parametric test (PG versus CG)
2 Median (interquartile range) or n (%)
doi:10.1371/journal.pone.0129927.t002
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Table 3. Vaccination data: number and percentage of children who received vaccinations before inclusion of MIPS Follow Up and during MIPS Fol-
low Up,
Prebiotics Group (PG)
(n = 232)
Control Group (CG)
(n = 243)
PG vs CG (P
value)1
Breast-fed Group (BG)
(n = 197)
CG vs BG (P
value)1
Before inclusion in MIPS FU (at
baseline)
-BMR 207 (89.2%) 216 (88.9%) 0.91 174 (88.3%) 0.85
-D(K)TP 10 (4.3%) 13 (5.3%) 0.60 12 (6.1%) 0.74
-D(K)TP plus HIB 101 (43.5%) 90 (37.0%) 0.15 110 (55.8%) <0.01
-HIB 11 (4.7%) 16 (6.6%) 0.39 3 (1.5%) <0.01
-Meningococ C 118 (50.9%) 121 (49.8%) 0.82 89 (45.2%) 0.34
-Pneumococ 70 (30.2%) 77 (31.7%) 0.72 74 (37.6%) 0.20
-Miscellaneous 27 (11.6%) 34 (14.0%) 0.44 42 (21.3%) 0.04
From inclusion to 4th birthday
-BMR 3 (1.3%) 1 (0.4%) 0.29 4 (2.0%) 0.11
-D(K)TP 45 (19.4%) 50 (20.6%) 0.75 30 (15.2%) 0.15
-D(K)TP plus HIB 1 (0.4%) 0 (0%) 0.31 0 (0%) 1.00
-HIB 49 (21.1%) 57 (23.5%) 0.54 38 (19.3%) 0.29
-Meningococ C 9 (3.9%) 3 (1.2%) 0.07 8 (4.1%) 0.06
-Pneumococ 1 (0.4%) 3 (1.2%) 0.34 0 (0%) 0.12
-Miscellaneous 13 (5.6%) 14 (5.8%) 0.94 18 (9.1%) 0.18
From 4rth birthday to 5th
birthday
-BMR 1 (0.4%) 0 (0%) 0.31 4 (2.0%) 0.03
-D(K)TP 11 (4.7%) 12 (4.9%) 0.92 4 (2.0%) 0.11
-D(K)TP plus HIB 0 (0%) 1 (0.4%) 0.33 1 (0.5%) 0.88
-HIB 2 (0.9%) 4 (1.6%) 0.45 2 (1.0%) 0.57
-Meningococ C 2 (0.9%) 4 (1.6%) 0.45 7 (3.6%) 0.20
-Pneumococ 0 (0%) 1 (0.4%) 0.33 3 (1.5%) 0.22
-Miscellaneous 6 (2.6%) 6 (2.5%) 0.94 13 (6.6%) 0.03
1 Non-parametric test (PG versus CG; CG versus BG; PG not tested versus BG)
doi:10.1371/journal.pone.0129927.t003
Table 4. Adjusted frequency of febrile episodes per year from third to fifth birthday, median and 25–75 percentiles.
Prebiotics Group (PG)
(n = 232)
Control Group (CG)
(n = 243)
PG vs CG (P
value)1
Breast-fed Group (BG)
n = 197
CG vs BG (P
value)1
Fever 1.17 (0.50–2.08) 1.20 (0.52–2.57) 0.22 1.48 (0.65–2.60) 0.42
Coughing 2.55 (1.09–4.07) 2.63 (1.09–4.56) 0.38 3.02 (1.52–4.80) 0.24
Wheezing 0.03 (0.02–0.54) 0.03 (0.02–0.52) 0.18 0.04 (0.02–0.52) 0.09
Runny or blocked
nose
2.59 (1.02–5.26) 2.91 (0.99–4.95) 0.93 3.62 (1.97–5.76) 0.05
Vomiting 0.87 (0.04–1.56) 0.91 (0.09–1.55) 0.46 1.00 (0.47–1.93) 0.70
Diarrhoea 0.51 (0.03–1.07) 0.53 (0.03–1.51) 0.22 0.57 (0.04–1.55) 0.53
1 Van Elteren test (PG versus CG; CG versus BG; PG not tested versus BG)
The term ‘adjusted’ reﬂects to the statistical ‘correction’ for zero values for those cases with zero illness episodes.
doi:10.1371/journal.pone.0129927.t004
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control formula exclusively for the first four months of life (20 weeks) or who had been breast-
fed exclusively for the first four months of life (20 weeks), had completed the MIPS1 until their
first birthday, and had completed the follow-up from their third to their fifth birthday only
(Fig 1). For this posthoc analysis we assessed the occurrence of febrile episodes between their
third to their fifth birthday. No statistically significant difference in the PG versus the CG was
found. We may speculate that the effect of prebiotics is found only at the time the prebiotics
are given, i.e. the period during which the infants received the prebiotics-supplemented
Table 5. Duration of illness episodes in days from third to fifth birthday, median and 25–75 percentiles
PG (n = 232) CG (n = 243) PG vs CG (P value)1 BG (n = 197) CG vs BG (P value)1
Fever 4.0 (0.0–9.5) 6.0 (1.0–13.0) 0.08 5.0 (2.0–11.0) 0.60
Coughing 22.5 (8.0–42.5) 24.0 (9.0–50.0) 0.27 32.0 (10.0–55.0) 0.70
Wheezing 0.0 (0.0–0.2) 0.0 (0.0–0.2) 0.74 0.0 (0.0–0.3) 0.89
Runny or blocked nose 21.0 (5.0–61.0) 24.0 (6.0–60.0) 0.66 34.0 (10.0–79.0) 0.36
Vomiting 2.0 (0.0–4.0) 2.0 (0.0–5.0) 0.13 2.0 (0.0–5.0) 0.33
Diarrhoea 1.0 (0.0–4.0) 2.0 (0.0–7.0) 0.01 2.0 (0.0–6.0) 0.67
1 Van Elteren test (PG versus CG; CG versus BG; PG not tested versus BG)
PG—Prebiotics Group; CG—Control Group; BG—Breast-fed Group
doi:10.1371/journal.pone.0129927.t005
Table 6. Use of antibiotics from third to fifth birthday.
Antibiotic type PG (n = 232) CG (n = 243) PG vs CG (P value)1 BG (n = 197) CG vs BG (P value)1
Pheneticilline 3 (1.3%) 3 (1.2%) 0.95 - 0.12
Phenoxymethylpenicilline 5 (2.2%) 11 (4.6%) 0.15 11 (5.6%) 0.61
Amoxicillin plus clavulanic acid 42 (18.1) 61 (25.1%) 0.06 43 (21.8) 0.42
Amoxicillin 47 (20.3%) 47 (19.3%) 0.80 27 (13.7%) 0.12
Sulfonamides plus trimethoprim 2 (0.9) 4 (1.6%) 0.44 - 0.07
Cefalosporines or ﬂuoroquinolones 2 (0.9%) 1 (0.4%) 0.54 1 (0.5%) 0.88
2nd generation cephalosporines 19 (8.2%) 16 (6.6%) 0.50 20 (10.2%) 0.18
3rd generation cephalosporines 21 (9.1%) 23 (9.5%) 0.88 29 (14.7%) 0.09
Macrolides 31 (13.4%) 35 (14.4%) 0.74 19 (9.6%) 0.13
Nitrofurantoine - 2 (0.8%) 0.17 - 0.20
1 Non-parametric test (PG versus CG; CG versus BG; PG not tested versus BG)
PG—Prebiotics Group; CG—Control Group; BG—Breast-fed Group
Number and percentage of children per study group having one or more doses of antibiotics
doi:10.1371/journal.pone.0129927.t006
Table 7. Use of antipyretics from third to fifth birthday.
Antipyretic type PG (n = 232) CG (n = 243) PG vs CG (P value)1 BG (n = 197) CG vs BG (P value)1
Paracetamol 157 (67.7%) 165 (67.9%) 0.96 117 (59.4%) 0.06
Ibuprofen or Naproxen 67 (28.9%) 72 (29.6%) 0.86 81 (41.1%) 0.01
1 Non-parametric test (PG versus CG; CG versus BG; PG not tested versus BG)
PG—Prebiotics Group; CG—Control Group; BG—Breast-fed Group
Number and percentage of children per study group having received one or more doses of antipyretics
doi:10.1371/journal.pone.0129927.t007
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formula as the greater part of their nutritional intake. After this period other products increas-
ingly predominate the nutritional intake of the child and the effect of prebiotics may fade away.
Although it might be speculated that the effect of the study formula was limited because this
was often combined with breastfeeding, this was, in fact, not the case: 67–85% of children re-
ceived exclusive study formula feeding (Table 1). However, the frequency of febrile episodes in
this healthy non-atopic study population in developed countries may be too low to demonstrate
a statistically significant effect: in the MIPS 1 study overall there were 1.2 fever episodes per
year, and in the MIPS follow up study 1.2 to 1.5 fever episodes per year. Aside from the low oc-
currence of the main study outcome (i.e. the frequency of febrile episodes), another limitation
of this study is the substantial number of children which were lost to follow up since the start of
the RCT (60% of MIPS1 participants were included). The main reason for this is likely to be the
relatively long time interval (two years) between the end of the RCT and the start of the follow
up study. Additionally, about a third of those not included in the follow up study were children
who did not complete the RCT (n = 129). We did a post hoc sample size calculation with the as-
sumption of two febrile episodes per year (and two years of observation) and a reduction of10%
in the intervention group (alpha 0.05 and power 0.80, two-sided) resulting in 1203 children per
group. These numbers may suggest that the power of the study is limited. However its use is not
primarily interpreting data. An indication of the value of the study results may come from the
95% confidence interval limits for the difference between PG and CG which are -0.74 and 0.40,
with a mean difference of -0.17 (Least Square Means, ANCOVA). It is very unlikely that the dif-
ference between PG and CG is more than one fever episode per year. [16]
If an effect of prebiotic supplementation exists, this is likely to be small and not clinically rel-
evant. We found only one difference in baseline characteristics in the original MIPS1 study
population versus the MIPS follow-up study population, but this difference (number of rooms
in the household) was similar in the PG and CG. Thus, although the original MIPS1 study
group and the current MIPS follow up group differ as to this one baseline characteristic, this is
unlikely to affect the validity of the comparison between the PG and CG.
The incidence of reported febrile episodes being lower that expected may at least partly be
explained by the relatively very healthy study population (i.e. without a family history of atopic
disease). The incidence of febrile episodes also may have been influenced by the fact that the
main outcome (febrile episodes) relied on parental reports. However, this outcome is close to
everyday practice in the way that illnesses are recognised in families with young children. By
prospective documentation (using a diary, repeated telephone calls and visits) any loss of infor-
mation was further minimalised. An underestimation of the number of febrile episodes may
have been caused by the use of rectal temperature measurements since many parents currently
prefer the use of a tympanic thermometer. Based on our three-monthly telephone contact with
the parents our impression is that for the purpose of the study parents all were highly compli-
ant with all aspects of the study, including the use of a rectal thermometer. We cannot exclude
with certainty that no febrile episodes were missed. Data using more objective outcome mea-
sures such as GP or pediatrician visits were not collected. Clear and uniform criteria would
probably result in the discounting of at least some illness episodes not fulfilling the criteria.
Data on the use of antibiotics or antipyretics do not show clinically relevant differences be-
tween the two study formula groups (PG and CG). We conclude that an effect of prebiotic sup-
plementation in the first year of life is unlikely to reduce the number of infections at age three
to five years.
Our data suggested a higher frequency of ‘runny or blocked nose’ (Table 3) in the non-ran-
domised BG compared to the CG. We found similar results in MIPS1. This difference may be
associated with a different parental attitude towards illness of their children in the non-rando-
mised BG. As a group breast feeding parents have a higher socioeconomic and educational
Febrile Episodes after Prebiotic Supplementation - MIPS Follow Up
PLOSONE | DOI:10.1371/journal.pone.0129927 June 15, 2015 9 / 12
level compared to parents who choose to formula feed their child. [17]Recent studies from de-
veloped countries demonstrated a clear association of breastfeeding with fewer infections. [18]
Problems with controlling for possible confounders such as hereditary and household factors
remain. [17]
In this study data about nutritional habits have not been collected. Recent studies showed
influence of dietary micronutrient intake on the occurrence of infections. Most of these studies
have been done in developing countries [19] in specific patient groups [20], or do not present
data about infections [21]. It is difficult to extrapolate these study results to other populations.
In this study we supplemented the infant formula with three oligosaccharides: neutral short-
chain galacto-oligosaccharides, neutral long-chain fructo-oligosaccharides, and pectin-derived
acidic oligosaccharides. As yet, there is no clarity as to the optimal composition and amount of
prebiotics. Thus far, most studies used a combination of short-chain galacto-oligosaccharides
and long-chain fructo-oligosaccharides. A study in mice showed a stimulatory effect on the Th1
type immune response when pectin-derived acidic oligosaccharides were added to the mixture.
(7) A recent RCT demonstrated that a mixture containing neutral and acidic oligosaccharides
added to the milk of breast milk-fed and to the formula of formula-fed preterm babies did not
reduce the occurrence of infectious diseases in these infants. [22,23] Differences in the composi-
tion of the prebiotic mixtures are small, but it is unknown if these may lead to different results.
The results of our study cannot be extrapolated to other prebiotics.
The results obtained in our previous studies and in the present study, do not support the use
of this mixture to reduce the frequency of infections in children up to five years of age. This
conclusion should be taken with caution because the power of this present study is limited by
the sample size and the low frequency of the main outcome parameter.
Conclusion
Although our study has limited power, it does not support the notion that this specific prebio-
tics mixture neutral short chain galacto-oligosaccharides and long chain fructo-oligosaccha-
rides 6.8 g/L, ratio 9:1 and pectin derived acidic oligosaccharides 1.2 g/L used in standard
formula during infancy prevents infection as it has not decreased febrile episodes in non-atopic
children between their third and fifth birthdays.
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